Therapeutic Drug Monitoring Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by the Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis. However, Alternatives to conventional TDM may challenge the growth of this market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155350443
Browse in-depth TOC on “Antiepileptic Drug Monitoring Industry”
178 – Tables
50 – Figures
221 – Pages
Antiarrhythmic Drug Monitoring Industry Dynamics:
Drivers:
- Importance of TDM in organ transplant procedures
- Use of TDM across various therapeutic fields
- Increasing preference for precision medicine
- Growing focus on R&D related to TDM
- Technological advancements
Restraints:
- Requirement of high capital investments
- Reluctance of small hospitals to offer TDM services
Opportunities:
- Increasing adoption in the treatment of autoimmune diseases
Challenges:
- Alternatives to conventional TDM
- Operational barriers faced in conducting TDM
Key Market Players:
The significant players in the Therapeutic Drug Monitoring industry are Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ARK Diagnostics, Inc. (US), apDia Group (Belgium), Immundiagnostik AG (Germany), and Sekisui Medical Co. Ltd. (Japan).
Recent Developments:
- In May 22, Theradiag (France) Announced the launch of ez-Track1, a Point-of-Care Testing solution for TDM.
- In Jan 2021, Theradiag (France) Announced CE marking for four new i-Tracker test kits for biotherapy monitoring.
Report Link: ( Therapeutic Drug Monitoring Market )
